-transparent.png){kind=logo}
OBJECTIVE To investigate the role of recombinant human hematopoietic growth factors (HGFs) in the treatment of myelodysplastic syndromes (MDS) patients. METHODS CD34+ cells from 16 MDS patients were purified up to 96% approximately 99% by means of a immunomagnetic beads sorting system. The effects of individual and combination of HGFs on the proliferation and differentiation of the CD34+ cells were studied in semi -solid cultures. RESULTS CD34+ cells were impaired and none of the individual HGF (GM-CSF, IL-3, SCF) could effectively support their proliferation and differentiation. rh-SCF combined with GM-CSF, IL-3 or Epo could partly increase the colony forming capacity of MDS hematopoietic progenitor, however, an increase of undifferentiated blast cells colonies occurred in some high-risk MDS patients at the same time. CONCLUSIONS Proper combination of HGFs was essential for improving hematopoiesis in MDS patients.
X Yang, and
X Gu, and
X Pei, and
L Zhu
September 1990,
Cancer genetics and cytogenetics,
X Yang, and
X Gu, and
X Pei, and
L Zhu
November 2003,
Current hematology reports,
X Yang, and
X Gu, and
X Pei, and
L Zhu
October 2011,
Seminars in oncology,
X Yang, and
X Gu, and
X Pei, and
L Zhu
May 1994,
Leukemia,
X Yang, and
X Gu, and
X Pei, and
L Zhu
January 1991,
Leukemia research,
X Yang, and
X Gu, and
X Pei, and
L Zhu
June 1997,
International journal of hematology,
X Yang, and
X Gu, and
X Pei, and
L Zhu
June 1992,
Hematology/oncology clinics of North America,
X Yang, and
X Gu, and
X Pei, and
L Zhu
January 2011,
Cancer treatment and research,
X Yang, and
X Gu, and
X Pei, and
L Zhu
April 1999,
Leukemia research,
X Yang, and
X Gu, and
X Pei, and
L Zhu
January 1991,
Acta haematologica Polonica,
